{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:37:16Z","timestamp":1778801836410,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.revmed.2024.03.012","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T05:12:43Z","timestamp":1717650763000},"page":"474-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["D\u00e9veloppement clinique des th\u00e9rapeutiques anti-facteur XII ciblant la thrombo-inflammation"],"prefix":"10.1016","volume":"45","author":[{"given":"T.","family":"Munoz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.K.","family":"Bentounes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Melicine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Smadja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2024.03.012_bib0120","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/13543776.2021.1945580","article-title":"Factor XII(a) inhibitors: a review of the patent literature","volume":"31","author":"Kalinin","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.revmed.2024.03.012_bib0125","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.03.012_bib0130","first-page":"69","article-title":"Development of new anticoagulant in 2023: prime time for anti-factor XI and XIa inhibitors","volume":"48","author":"Bentounes","year":"2023","journal-title":"J Med Vasc"},{"key":"10.1016\/j.revmed.2024.03.012_bib0135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/rth2.12235","article-title":"Factor XII\u00a0\u2013\u00a0what's important but not commonly thought about","volume":"3","author":"Schmaier","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.03.012_bib0140","doi-asserted-by":"crossref","first-page":"2201360","DOI":"10.1002\/adhm.202201360","article-title":"Mechanisms for reduced fibrin clot formation on liquid-infused surfaces","volume":"11","author":"Hong","year":"2022","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.revmed.2024.03.012_bib0145","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/ATVBAHA.114.304114","article-title":"Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms","volume":"34","author":"Gould","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.revmed.2024.03.012_bib0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/ATVBAHA.122.317162","article-title":"Thromboinflammation: from atherosclerosis to COVID-19","volume":"42","author":"Wagner","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.revmed.2024.03.012_bib0155","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood.2023019861","article-title":"Hereditary angioedema and thrombosis","volume":"141","author":"Gailani","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.03.012_bib0160","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/jth.12295","article-title":"Factor XII promotes blood coagulation independent of factor XI in the presence of long chain polyphosphate","volume":"11","author":"Puy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.03.012_bib0165","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.03.012_bib0170","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1111\/jth.15488","article-title":"Generation of a humanized FXII knock-in mouse\u00a0\u2014\u00a0a powerful model system to test novel anti-thrombotic agents","volume":"19","author":"Beck","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.03.012_bib0175","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11239-019-01819-8","article-title":"Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period","volume":"47","author":"Girolami","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.revmed.2024.03.012_bib0180","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.03.012_bib0185","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.03.012_bib0190","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.jacc.2019.08.1027","article-title":"Are ticks the answer to medical device-associated clotting?","volume":"74","author":"Weitz","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2024.03.012_bib0195","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation with an inhibitor of factors XIa and XIIa during cardiopulmonary bypass","volume":"74","author":"Pireaux","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2024.03.012_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.12.1570","article-title":"Development and characterization of an anti-FXIIa monoclonal antibody for the treatment of hereditary angioedema","volume":"135","author":"Cao","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2024.03.012_bib0205","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cts.13192","article-title":"Pharmacokinetic\/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated factor XII inhibitor garadacimab (CSL312)","volume":"15","author":"Pawaskar","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.revmed.2024.03.012_bib0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00408-023-00615-9","article-title":"Efficacy and safety of garadacimab in combination with standard of care treatment in patients with severe COVID-19","volume":"201","author":"Papi","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.revmed.2024.03.012_bib0220","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2024.03.012_bib0215","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","article-title":"Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2\u00a0trial","volume":"399","author":"Craig","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2024.03.012_bib0225","doi-asserted-by":"crossref","first-page":"1287487","DOI":"10.3389\/fphar.2023.1287487","article-title":"Oral FXIIa inhibitor KV998086\u00a0suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation","volume":"14","author":"Clermont","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.revmed.2024.03.012_bib0115","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/bloodadvances.2022007586","article-title":"Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation","volume":"7","author":"Tweddell","year":"2023","journal-title":"Blood Adv"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324000924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324000924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T21:33:31Z","timestamp":1723325611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866324000924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0248866324000924"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2024.03.012","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9veloppement clinique des th\u00e9rapeutiques anti-facteur XII ciblant la thrombo-inflammation","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2024.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}